Cat. No.: HY-10466

Daclatasvir

(Synonyms: BMS-790052; EBP 883)

48 Cited Publications

Customer Review

Based on 48 publication(s) in Google Scholar

Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively.

For research use only. We do not sell to patients.

Purity: 98.68%
CAS No.: 1009119-64-5
Formula: C₄₀H₅₀N₈O₆
Molecular Weight:738.88

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Daclatasvir Chemical Structure

CAS No.: 1009119-64-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (48)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) and 33 pM (HCV replicon genotype 5a)^[1]
Kd: 8 nM (NS5A33-202) and 210 nM (NS5A26-202)^[2]
IC50: 1.5 µM (OATP1B) and 3.27 µM (OATP1B3)^[3]

Cellular Effect

Cell Line	Type	Value	Description	References
Calu-3	CC₅₀	38 μM Compound: Daclatasvir	Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay	[PMID: 36965227]
CCRF-CEM	CC₅₀	10 μM Compound: BMS-790052	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 26099532]
CCRF-CEM	CC₅₀	21 μM Compound: BMS, BMS-790052	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 23466233]
CCRF-CEM	CC₅₀	9.6 μM Compound: BMS-790052	Cytotoxicity against human CEM cells after 3 days Cytotoxicity against human CEM cells after 3 days	[PMID: 22507961]
CCRF-CEM	CC₅₀	9.6 μM Compound: BMS-790052	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 22704887]
Huh-7	CC₅₀	>1 μM Compound: BMS, BMS-790052	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 23466233]
Huh-7	CC₅₀	>1 μM Compound: BMS-790052	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 22704887]
Huh-7	CC₅₀	>10 μM Compound: 33	Cytotoxicity against human HuH7 cells infected with HCV1b by Alamar blue fluorescence assay Cytotoxicity against human HuH7 cells infected with HCV1b by Alamar blue fluorescence assay	[PMID: 24521299]
Huh-7	CC₅₀	>15 μM Compound: BMS-790052	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 26099532]
Huh-7	EC₅₀	0.003 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by cell-based replicon assay Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by cell-based replicon assay	[PMID: 25148100]
Huh-7	EC₅₀	0.009 nM Compound: 33	Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay	[PMID: 24521299]
Huh-7	EC₅₀	0.009 nM Compound: 6, BMS-790052	Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay	[PMID: 24320933]
Huh-7	EC₅₀	0.009 nM Compound: DCV, BMS-790052	Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication	[PMID: 26077493]
Huh-7	EC₅₀	0.01 nM Compound: BMS, BMS-790052	Antiviral activity against HCV 1b infected in human HuH7 cells by in vitro replicon assay Antiviral activity against HCV 1b infected in human HuH7 cells by in vitro replicon assay	[PMID: 23466233]
Huh-7	EC₅₀	0.023 nM Compound: 1a	Inhibition of NS5A in HCV genotype-1b infected in human HuH7 cells by luciferase reporter gene assay Inhibition of NS5A in HCV genotype-1b infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453810]
Huh-7	EC₅₀	0.05 nM Compound: 33	Antiviral activity against HCV1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay Antiviral activity against HCV1a infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by FRET assay	[PMID: 24521299]
Huh-7	EC₅₀	0.05 nM Compound: 6, BMS-790052	Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay Antiviral activity against HCV genotype 1a H77 infected in human HuH7 cells assessed as inhibition of viral RNA replication after 3 days by renilla luciferase reporter gene assay	[PMID: 24320933]
Huh-7	EC₅₀	0.051 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 5a infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 5a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	0.073 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 1b infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 1b infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	0.14 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 1a infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 1a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	0.14 nM Compound: 1a	Inhibition of NS5A in HCV genotype-1a infected in human HuH7 cells by luciferase reporter gene assay Inhibition of NS5A in HCV genotype-1a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453810]
Huh-7	EC₅₀	0.41 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 4a infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 4a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	0.45 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 6a infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 6a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	0.67 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 2a infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 2a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	0.67 nM Compound: 1, BMS-790052	Antiviral activity against HCV genotype 3a infected in human HuH7 cells by luciferase reporter gene assay Antiviral activity against HCV genotype 3a infected in human HuH7 cells by luciferase reporter gene assay	[PMID: 25453811]
Huh-7	EC₅₀	180 pM Compound: BMS-790052	Antiviral activity against HCV genotype 1b expressing NS5A Y93H mutant infected in human HuH7 cells assessed as reduction in viral RNA replication Antiviral activity against HCV genotype 1b expressing NS5A Y93H mutant infected in human HuH7 cells assessed as reduction in viral RNA replication	[PMID: 26099532]
Huh-7	EC₅₀	28 pM Compound: DCV, BMS-790052	Antiviral activity against HCV genotype 1b JFH-1 infected in human HuH7 cells assessed as inhibition of viral replication Antiviral activity against HCV genotype 1b JFH-1 infected in human HuH7 cells assessed as inhibition of viral replication	[PMID: 26077493]
Huh-7	EC₅₀	35 pM Compound: BMS-790052	Antiviral activity against HCV genotype 1b expressing NS5A L31V mutant infected in human HuH7 cells assessed as reduction in viral RNA replication Antiviral activity against HCV genotype 1b expressing NS5A L31V mutant infected in human HuH7 cells assessed as reduction in viral RNA replication	[PMID: 26099532]
Huh-7	EC₅₀	4 pM Compound: BMS-790052	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction in viral RNA replication Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction in viral RNA replication	[PMID: 26099532]
Huh-7	EC₅₀	48 pM Compound: BMS-790052	Antiviral activity against wild type HCV genotype 1b infected in human HuH7 cells assessed as reduction in viral RNA replication Antiviral activity against wild type HCV genotype 1b infected in human HuH7 cells assessed as reduction in viral RNA replication	[PMID: 26099532]
Huh-7	EC₅₀	6.6 pM Compound: BMS-790052	Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication by RT-PCR analysis Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication by RT-PCR analysis	[PMID: 22507961]
PBMC	CC₅₀	19 μM Compound: BMS-790052	Cytotoxicity against human PBMC after 3 days Cytotoxicity against human PBMC after 3 days	[PMID: 22507961]
PBMC	CC₅₀	19 μM Compound: BMS, BMS-790052	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 23466233]
PBMC	CC₅₀	19 μM Compound: BMS-790052	Cytotoxicity against human PBMC cells Cytotoxicity against human PBMC cells	[PMID: 22704887]
PBMC	CC₅₀	19 μM Compound: BMS-790052	Cytotoxicity against PBMC (unknown origin) Cytotoxicity against PBMC (unknown origin)	[PMID: 26099532]
Vero	CC₅₀	21 μM Compound: BMS-790052	Cytotoxicity against african green monkey Vero cells after 3 days Cytotoxicity against african green monkey Vero cells after 3 days	[PMID: 22507961]
Vero	CC₅₀	21 μM Compound: BMS-790052	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 22704887]
Vero	CC₅₀	21 μM Compound: BMS-790052	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 26099532]
Vero	CC₅₀	9.6 μM Compound: BMS, BMS-790052	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 23466233]

In Vitro

Daclatasvir (BMS-790052) demonstrates potent inhibitory activity towards all genotypes tested, with EC₅₀ values ranging from 9 pM to 146 pM. Daclatasvir inhibits HCV replicon genotype 1a, 1b, 2a, 3a, 4a and 5a with EC₅₀ values of 50 pM, 9 pM, 71 pM, 146 pM, 12 pM and 33 pM, respectively. Daclatasvir is a potent inhibitor of the JFH-1 genotype 2a infectious virus that replicates in cell culture (EC₅₀=28 pM)^[1]. Daclatasvir (BMS-790052) binds tightly to NS5A33-202 and NS5A26-202 with K_ds of 8 nM and 210 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Daclatasvir (BMS-790052; 30 mg/kg; oral administration; daily; for 27 days) treatment reduces serum HCV RNA titers very rapidly by ~1.5 log₁₀ at day 3^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID male mice (5 weeks of age, 18-20 g) bearing HCV RNA-transfected cells^[4]
Dosage:

30 mg/kg
Administration:

Oral administration; daily; for 27 days
Result:

Reduced serum HCV RNA titers very rapidly by ~1.5 log₁₀ at day 3.

Chemical Information

CAS No. 1009119-64-5
Appearance Solid
Molecular Weight 738.88
Formula C₄₀H₅₀N₈O₆
Color Light yellow to yellow
SMILES

O=C([C@@H](NC(OC)=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4
Synonyms

BMS-790052; EBP 883
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (48)

All WB

Sort by:

Journal Impact Factor

Hepatology

Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. [Abstract]

2019 May;69(5):1861-1872. PMID: 29425396
EMBO Mol Med

Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa. [Abstract]

2024 Apr;16(4):870-884. PMID: 38462666
Biomed Pharmacother

FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells. [Abstract]

2024 Sep 2:179:117325. PMID: 39226729
Biomed Pharmacother

A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. [Abstract]

2019 Aug:116:108976. PMID: 31103827
Cell Rep

Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation. [Abstract]

2021 Nov 23;37(8):110049. PMID: 34788596
J Med Chem

2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. [Abstract]

2020 Jun 11;63(11):5972-5989. PMID: 32378892
Int J Radiat Oncol Biol Phys

Targeting Phosphatidylinositol 4-Kinase IIIα for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent. [Abstract]

2016 Nov 15;96(4):867-876. PMID: 27788957
EMBO Rep

Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication. [Abstract]

2016 Jul;17(7):1013-28. PMID: 27283940
Eur J Med Chem

Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism. [Abstract]

2018 Jan 1:143:1053-1065. PMID: 29232582

Daclatasvir purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Jan 1:143:1053-1065. [Abstract]

GS4.3 cells are treated with 7f (20 μM), or Telaprevir (0.5μM), Sofosbuvir (0.8 μM), Daclatasvir (0.15 μM) or solvent control for 6 days.

Daclatasvir purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2018 Jan 1:143:1053-1065. [Abstract]

Huh7.5 cells are infected with HCV and simultaneously treated with 7f (10 μM) or DAA (0.04 μM Simeprevir, 0.08 μM Sofosbuvir, or 16 pM Daclatasvir) or 7f plus DAA.
Mol Cancer Ther

Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]

2026 Jun 13. PMID: 42295240
J Gastroenterol

Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. [Abstract]

2019 May;54(5):449-458. PMID: 30684016
PLoS Pathog

Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation. [Abstract]

2018 Sep 18;14(9):e1007284. PMID: 30226904

Daclatasvir purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2018 Sep 18;14(9):e1007284. [Abstract]

Polyprotein expression efficiency is determined by Western-Blot using an antibody against NS3 and beta actin as loading control.
PLoS Pathog

Characterization of miR-122-independent propagation of HCV. [Abstract]

2017 May 11;13(5):e1006374. PMID: 28494029
Pharmaceuticals (Basel)

Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. [Abstract]

2022 Feb 18;15(2):242. PMID: 35215354
Front Pharmacol

Bicyclol Attenuates Liver Inflammation Induced by Infection of Hepatitis C Virus via Repressing ROS-Mediated Activation of MAPK/NF-κB Signaling Pathway. [Abstract]

2018 Dec 19:9:1438. PMID: 30618739
Front Pharmacol

Grape Seed Extract Attenuates Hepatitis C Virus Replication and Virus-Induced Inflammation. [Abstract]

2016 Dec 21:7:490. PMID: 28066241
Eur J Pharmacol

Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process. [Abstract]

2020 Sep 15;883:173323. PMID: 32622669
Eur J Pharmacol

Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I. [Abstract]

2019 Jun 15:853:111-120. PMID: 30902657
J Med Virol

Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon. [Abstract]

2023 Dec;95(12):e29290. PMID: 38102947
Hepatol Commun

Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α. [Abstract]

2017 Jul 13;1(6):550-563. PMID: 29404478
Int J Antimicrob Agents

Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1. [Abstract]

2015 Oct;46(4):381-8. PMID: 26163159
Antimicrob Agents Chemother

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. [Abstract]

2015 May;59(5):2496-507. PMID: 25666154
Antimicrob Agents Chemother

Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. [Abstract]

2014 Aug;58(8):4555-64. PMID: 24867984
Antimicrob Agents Chemother

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. [Abstract]

2014 Jun;58(6):3327-34. PMID: 24687498
Antimicrob Agents Chemother

Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction. [Abstract]

2013 Mar;57(3):1180-91. PMID: 23254429
Ann Hepatol

Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. [Abstract]

Nov-Dec 2019;18(6):816-824. PMID: 31594756
Antiviral Res

Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. [Abstract]

2020 May;177:104734. PMID: 32057770
Antiviral Res

Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. [Abstract]

2019 Nov;171:104612. PMID: 31542377
Drug Metab Dispos

A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters. [Abstract]

2019 Jul;47(7):768-778. PMID: 31068368
Antiviral Res

Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. [Abstract]

2017 Dec:148:5-14. PMID: 29074218
Antiviral Res

Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. [Abstract]

2017 Oct:146:191-200. PMID: 28935193
Sci Rep

Lobohedleolide suppresses hepatitis C virus replication via JNK/c-Jun-C/EBP-mediated down-regulation of cyclooxygenase-2 expression. [Abstract]

2018 Jun 6;8(1):8676. PMID: 29875371
J Virol

Novel permissive cell lines for complete propagation of hepatitis C virus. [Abstract]

2014 May;88(10):5578-94. PMID: 24599999
Viruses

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. [Abstract]

2018 Aug 28;10(9). pii: E462. PMID: 30154359
Virus Res

Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems. [Abstract]

2017 May 2:235:37-48. PMID: 28322919
Transpl Infect Dis

The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype. [Abstract]

2018 Feb;20(1). PMID: 29111569
PLoS One

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection. [Abstract]

2016 Jul 21;11(7):e0159511. PMID: 27442520
PLoS One

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175. [Abstract]

2016 Apr 22;11(4):e0152036. PMID: 27104614
PLoS One

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. [Abstract]

2015 Aug 11;10(8):e0134707. PMID: 26263487
J Hum Genet

Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. [Abstract]

2020 Jan;65(2):143-153. PMID: 31645655
bioRxiv

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]

2025 Oct 9:2025.10.08.681217. PMID: 41279001
University of Glasgow

2024 Mar.
bioRxiv

2020 May.
Charles University

2019 Jun.
Charles University

2019.
Oncotarget

Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling. [Abstract]

2017 Dec 21;9(5):5627-5640. PMID: 29464023
Seoul National University

2016 Aug.
Open Virol J

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells. [Abstract]

2014 Mar 7;8:1-8. PMID: 24799968

Daclatasvir purchased from MedChemExpress. Usage Cited in: Open Virol J. 2014 Mar 7;8:1-8. [Abstract]

The PKR activation block is not unique to CypI, DAAs also prevent the IFN-induced PKR activation in HCV-infected cells. JFH-1-infected Huh7.5.1 cells are treated with or without CypI (cyclosporine A and alisporivir), DAAs (the HCV NS5A inhibitor daclatasvir and the HCV protease inhibitor telaprevir) and an HIV-1 inhibitor (reverse transcriptase inhibitor emtricitabine). Results are representative of 4 independent experiments.

Solvent & Solubility

In Vitro:

DMSO : ≥ 40 mg/mL (54.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3534 mL

6.7670 mL

13.5340 mL

5 mM

0.2707 mL

1.3534 mL

2.7068 mL

10 mM

0.1353 mL

0.6767 mL

1.3534 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100. [Content Brief]

[2]. David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765. [Content Brief]

[3]. Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64. [Content Brief]

[4]. Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3534 mL	6.7670 mL	13.5340 mL	33.8350 mL
	5 mM	0.2707 mL	1.3534 mL	2.7068 mL	6.7670 mL
	10 mM	0.1353 mL	0.6767 mL	1.3534 mL	3.3835 mL
	15 mM	0.0902 mL	0.4511 mL	0.9023 mL	2.2557 mL
	20 mM	0.0677 mL	0.3383 mL	0.6767 mL	1.6917 mL
	25 mM	0.0541 mL	0.2707 mL	0.5414 mL	1.3534 mL
	30 mM	0.0451 mL	0.2256 mL	0.4511 mL	1.1278 mL
	40 mM	0.0338 mL	0.1692 mL	0.3383 mL	0.8459 mL
	50 mM	0.0271 mL	0.1353 mL	0.2707 mL	0.6767 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Daclatasvir

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Daclatasvir

Biological Activity

Chemical Information

Publications (48)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Daclatasvir

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Daclatasvir

Biological Activity

Chemical Information

Publications (48)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Daclatasvir Related Classifications

Cat. No.: HY-10466